Quantum BioPharma Secures Investor Relations Support

Introduction

Quantum BioPharma Ltd (NASDAQ: QNTM) is a Toronto-based biopharmaceutical company focused on developing solutions for neurodegenerative, inflammatory, and metabolic disorders, as well as consumer products related to alcohol detoxification. Founded in 1994, Quantum BioPharma’s product pipeline includes Lucid-MS, a patented compound targeting remyelination in multiple sclerosis, and unbuzzd™, a beverage aimed at alcohol detoxification. As of June 23, 2025, QNTM shares traded at USD 24.16 on NASDAQ, reflecting a 30.97% decline over a recent period, with a daily trading volume of 327,935 shares.

Corporate Structure

Quantum BioPharma employs between 11 and 50 professionals across research, clinical development, and commercialization. The headquarters is in Toronto, with operations including its wholly owned subsidiary Lucid Psycheceuticals. Key members of the leadership and advisory teams include:

• Zeeshan Saeed, CEO and Co-Founder
• Dr. Lakshmi P. Kotra, Senior Scientist and recipient of the Julia Levy Award, overseeing Lucid-MS development
• Kevin Harrington, inventor of the infomercial and original Shark Tank investor
• Gerry David, former CEO of Celsius Holdings, Inc.
• John Duffy Jr., former Vice President of National Sales at Coca-Cola

The company’s capital structure comprises Class A and Class B shares, alongside 48,951 options and 138,077 warrants. As of August 14, 2024, the company reported no debt and sufficient working capital to support operations through 2025.

Recent Developments

On February 11, 2025, Quantum BioPharma engaged MZHCI, LLC (MZ Group) under an initial agreement of two months at a cost of USD 10,000 per month to lead strategic investor relations and financial communications, with automatic monthly renewals thereafter.

On June 16, 2025, Malone Wealth Ventures LLC filed an Amendment to Schedule 13D, reporting beneficial ownership of 505,172 shares (14.8% of the common stock), indicating significant investor engagement.

On June 17, 2025, the company filed Form 6-K with the SEC, which included a press release under Exhibit 99.1 addressing corporate updates; further details are available in the SEC archive.

In August 2024, Quantum BioPharma launched unbuzzd™, a beverage designed to accelerate alcohol metabolism and restore mental alertness, which is licensed for consumer sales by Celly Nutrition.

Financial and Strategic Analysis

Quantum BioPharma carries no debt and maintains sufficient working capital for 2025. Key strategic assets include:

• Lucid-MS: A new chemical entity with over 14 years of preclinical research, shown to prevent and reverse myelin degradation in animal models. The phase 1 dosing of healthy volunteers was completed in early 2023, and the compound aims to explore a first-in-class regulatory pathway within a global multiple sclerosis market projected to reach USD 41 billion by 2033.
• unbuzzd™: A beverage aimed at addressing alcohol detoxification, targeting a consumer market expected to grow from USD 2.05 billion in 2022 to USD 6.2 billion by 2030. This product is distinguished as a clinically tested supplement demonstrating effectiveness in reducing blood alcohol concentration.

The company further diversifies revenue through strategic equity and royalty agreements with Celly Nutrition. Its exclusive intellectual property estate, collaborations with institutes such as the Krembil Brain Institute, and a skilled research and development team support its development pipeline.

Market Position and Industry Context

Quantum BioPharma operates at the intersection of high-value therapeutics and consumer wellness. In neurodegenerative therapeutics, Lucid-MS competes in a market that lacks curative options, offering a neuroprotective approach without immunosuppression. In the consumer health sector, unbuzzd™ addresses demand for effective alcohol detoxification, with distribution through e-commerce, retail, and on-premise channels. This dual focus enables the company to position itself against established pharmaceutical firms and emerging wellness brands.

tl;dr

QNTM shares traded at USD 24.16 on June 23, 2025, down 30.97%. Quantum BioPharma retained MZ Group for investor relations on February 11, 2025. Malone Wealth Ventures disclosed a 14.8% stake on June 16, 2025. The launch of unbuzzd™ occurred in August 2024, while Lucid-MS completed phase 1 dosing in early 2023. Upcoming developments include a planned phase 2 trial for Lucid-MS and a broader commercial rollout of unbuzzd™.